As per the latest market research conducted by FMI, the global respiratory pathogen testing kits market is expected to record a CAGR of 5.7% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of US$ 4,083.1 million. By 2033, the valuation is expected to be worth US$ 7,136.8 million.
The most prevalent illnesses that infect people are respiratory tract infections. It has been linked to less serious lower respiratory tract infections (LRTIs), such as pneumonia and bronchitis, as well as self-limiting upper respiratory tract infections (URTIs), like the common cold. Lower respiratory tract infections (LRTIs) have a considerable impact on disease burden and are a leading cause of hospitalization, morbidity, and death in kids and seniors.
The viral respiratory incidents per year in developed countries have been estimated between 5 and 10 in children under the age of six compared to 3 to 6 in those over this age, and acute respiratory infection continues to account for 35% to 45% of hospitalized patients, according to data from the National Institutes of Health. Thus, increasing the respiratory pathogen testing demand to a great extent.
Crucial Growth Factors of the Respiratory Pathogen Testing Kits Market:
| Attributes | Value |
|---|---|
| Respiratory Pathogen Testing Kits Value (2022) | US$ 3,852.9 million |
| Respiratory Pathogen Testing Kits Market Expected Value (2023) | US$ 4,083.1 million |
| Respiratory Pathogen Testing Kits Market Forecast Value (2033) | US$ 7,136.8 million |
| Respiratory Pathogen Testing Kits Market Expected CAGR (2023 to 2033) | 5.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 5.86% |
| H1, 2022 Projected | 6.06% |
| H1, 2022 Outlook | 5.96% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (+) 10 ↑ |
According to Future Market Insights' analysis, the global respiratory pathogen testing kits market expects to increase by 10 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during the H1-2022 outlook period showed a dip of 10 BPS.
Given the constraints of quick testing, which can't assess widespread coinfection detection, the market for respiratory pathogen testing kits sees a fall in BPS values. Testing kits also have drawbacks, including a lengthy turnaround time, labor-intensive procedures, and low sensitivity.
However, due to the high specificity of RP panel tests for many viruses and bacteria in the respiratory tract, the market is likely to witness an upswing in terms of growth with the introduction of RP tests.
The market is subject to changes as per the regulatory norms and product adoption rates, concerning the macro and industry dynamics. The key developments in the market include the development of PCR-based diagnostic test panels to detect and differentiate common respiratory pathogens simultaneously.
Principal Consultant
Sales of respiratory pathogen testing kits expanded at a rapid CAGR of 9.8% from 2018 to 2022.
A respiratory pathogen testing kit can be used to detect respiratory infections by analyzing blood, fluids, or samples from the affected area of the body.
Respiratory pathogen testing kits can identify the most common illnesses' genetic material (RNA/DNA). It can recognize a variety of pathogenic bacteria and discover germs that conventional techniques, like blood cultures, can lack. Several test kits can identify specific strains or subgroups of microorganisms.
Uncontrolled ingestion of different gases, such as sulfur dioxide and carbon monoxide, can obstruct the respiratory tract. Many bacterial, fungal, and viral illnesses of the respiratory system can be identified with respiratory pathogen testing kits.
Lateral flow tests, also referred to as immunochromatographic assays, reverse transcription-polymerase chain reaction (RT-PCR) tests, direct fluorescent antibody (DFA) tests, solid-phase assays, agglutination assays, and flow-through assays are among the various types of respiratory pathogen testing.
Chronic Obstructive Pulmonary Disease (COPD) is a lung disease that causes a decline in airflow over time. As per the WHO, low and middle-income nations account for 90% of COPD deaths.
Over 251 million instances of chronic obstructive pulmonary disease were reported globally, according to the Global Burden of Disease survey. In the upcoming years, it is anticipated to increase as the global population ages and people's lifestyles change. The market for respiratory pathogen testing kits is growing as early detection and treatment become more important.
The respiratory pathogen testing kits market is predicted to record a significant CAGR of 5.7% from 2023 to 2033 and is expected to reach a valuation of US$ 7,136.8 million by 2033.
Respiratory Pathogen Testing Kits Market:
| Differentiating Aspects | Respiratory Pathogen Testing Kits Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 5.7% |
| Market Valuation (2023) | US$ 4,083.1 million |
| Growth Factors | Rising chronic illness prevalence and increasing pathogen testing and preventative healthcare awareness. |
| Future Opportunities | The market for respiratory pathogen testing kits is driven by a significant increase in respiratory illness incidences. |
| Market Trends | Future market demand is likely to be profitable since developing and emerging economies have access to improved healthcare facilities. |
Blood Transfusion Devices Market:
| Differentiating Aspects | Blood Transfusion Devices Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 5.9% |
| Market Valuation (2023) | US$ 4,975.77 million |
| Growth Factors | Blood-related illnesses and chronic renal disease are becoming more common. |
| Future Opportunities | Issues such as a strict regulatory framework and high costs associated with the treatment of blood and its components are likely to drive market expansion. |
| Market Trends | The transition from manual testing and instrumentation to semi-automated and fully automated equipment is intensifying with the development of novel molecular platforms. |
Blood Transfusion Market:
| Differentiating Aspects | Blood Transfusion Market |
|---|---|
| Anticipated CAGR (2023 to 2033) | 7% |
| Market Valuation (2023) | US$ 4.69 billion |
| Growth Factors | Blood transfusion demand is predicted to rise due to an increase in anemic people who require red blood cell transfusions to treat their condition. |
| Future Opportunities | The use of stem cell technologies to manufacture lab-grown blood cells for human transfusion is one of the advanced research procedures and is expected to create multiple opportunities. |
| Market Trends | The emergence of cost-effective and novel technology to inactivate or minimize the risk of infection is increasing demand for a pathogen reduction system. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increased Research and Development Funding Improve Respiratory Pathogen Testing Systems Sales
Market Growth is Boosted by Increased Funding for Respiratory Diagnostics
Rising Incidence of Chronic Diseases is Likely to Increase the Usage of Respiratory Pathogen Testing Equipment
Need for Advanced Diagnostic Testing Methods Fuelling Demand for Respiratory Pathogen Testing Kits
Strict Laws for the Mining Sector Increase the Usage of Respiratory Pathogen Testing Kits
High Product Costs and a Lack of Consumer Awareness are Expected to Restrain the Market's Growth for Respiratory Pathogen Testing Kits.
The United States market is projected to be the lucrative market for respiratory pathogen testing kits. The market is anticipated to record a CAGR of 6.6% and is anticipated to continue on this path in the years to come. A sedentary lifestyle, along with COVID-19 and other existing viral, bacterial, and fungal diseases, is driving the market in this region.
In response to the increased cases of COVID-19, the respiratory pathogen testing kit market in the Asia Pacific is gaining momentum. Air pollution is another market-stimulating factor. More than 20 of the most polluting nations in the world are located in the Asia Pacific, according to IQAir. Sales of respiratory pathogen testing kits are rising as a result of the congestion of the respiratory tract brought on by uncontrolled ingestion of carbon monoxide and sulfur dioxide.
The top genomics company in the world, BGI Group, has partnered with China's military on projects ranging from mass testing for respiratory viruses to brain science, according to a Reuters review of research, patent filings, and other publications.
According to an analysis of more than 40 publicly available documents and research articles in Chinese and English, BGI has connections to the People's Liberation Army (PLA), including research with China's top military supercomputing professionals. China was the location where the COVID-19 pandemic started, and it swiftly spread throughout the world. Since that time, the diagnostic industry has expanded rapidly.
| Countries | United States |
|---|---|
| CAGR (2018 to 2022) | 10.6% |
| CAGR (2023 to 2033) | 6.6% |
| Valuation (2033) | US$ 2,438.4 million |
| Countries | United Kingdom |
|---|---|
| CAGR (2018 to 2022) | 7.6% |
| CAGR (2023 to 2033) | 6.0% |
| Valuation (2033) | US$ 379.2 million |
| Countries | China |
|---|---|
| CAGR (2018 to 2022) | 10.1% |
| CAGR (2023 to 2033) | 6.3% |
| Valuation (2033) | US$ 585.7 million |
| Countries | Germany |
|---|---|
| CAGR (2018 to 2022) | 10.3% |
| CAGR (2023 to 2033) | 6.0% |
| Valuation (2033) | US$ 552.6 million |
A type of viral diagnostic test known as a Nucleic Acid Amplification Test, or NAAT, is used to identify SARS-CoV-2, the virus that causes COVID-19. Genetic material detectors are NAATs (nucleic acids). The RNA (ribonucleic acid) sequences that make up the virus' genetic information are precisely identified by SARS-CoV-2 NAATs.
NAATs are utilized for SARS-CoV-2 test samples from the upper or lower respiratory tracts. The type of specimen used for SARS-CoV-2 testing depends on both the test being run and the manufacturer's instructions.
The advancement of nucleic acid amplification testing technology is being fueled by the rising incidence of contagious diseases, the growing demand for better diagnostic tools, and increased funding for the creation of novel biotechnological diagnostic techniques. Now, nucleic acid amplification testing is anticipated to hold a 44.6% market share overall.
The presence of several manufacturers and key market players operating at the worldwide level defines the respiratory pathogen testing kits market. Leading respiratory pathogen testing equipment manufacturers are concentrating their efforts on developing unique testing kits that are expected to aid in obtaining results quickly. They are investing heavily to get a competitive advantage over one another.
Significant Key Players in the Market:
Recent Development:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; The Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Türkiye, South Africa, GCC Countries |
| Key Market Segments Covered | Product, Infection/Symptom, Technology, End User, Region |
| Key Companies Profiled | Thermo Fisher Scientific; Abbott Laboratories; Danaher Corporation; Becton, Dickinson, and Company; Hoffmann-La Roche Ltd.; bioMérieux Inc.; Altona Diagnostics; MyLab |
| Pricing | Available upon Request |
The market is estimated to reach US$ 7,136.8 million by 2033.
The market is expected to record a growth of 5.7% through 2033.
Surging rate of chronic diseases and increasing funding for respiratory diagnostics.
Growing awareness about preventative healthcare.
Surging incidence of respiratory illness may create opportunity for market players.
1. Executive Summary | Respiratory Pathogen Testing Kits Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033 5.3.1. RT PCR Kits 5.3.2. DFA Kits 5.3.3. ELISA Kits 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Infection 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Infection, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Infection, 2023 to 2033 6.3.1. Enterovirus Infection 6.3.2. Human Coronavirus Infection 6.3.3. Influenza Virus Infection 6.3.4. Respiratory Syncytial Virus Infection 6.3.5. Rhinovirus Infection 6.4. Y-o-Y Growth Trend Analysis By Infection, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Infection, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Diagnostic Centres 7.3.3. Speciality Clinics 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Product 9.2.3. By Infection 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Infection 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product 10.2.3. By Infection 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Infection 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Product 11.2.3. By Infection 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Infection 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Product 12.2.3. By Infection 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Infection 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product 13.2.3. By Infection 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Infection 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Product 14.2.3. By Infection 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Infection 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product 15.2.3. By Infection 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product 15.3.3. By Infection 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Product 16.1.2.2. By Infection 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Product 16.2.2.2. By Infection 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Product 16.3.2.2. By Infection 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Product 16.4.2.2. By Infection 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Product 16.5.2.2. By Infection 16.5.2.3. By End User 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Product 16.6.2.2. By Infection 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Product 16.7.2.2. By Infection 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Product 16.8.2.2. By Infection 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Product 16.9.2.2. By Infection 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Product 16.10.2.2. By Infection 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Product 16.11.2.2. By Infection 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Product 16.12.2.2. By Infection 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Product 16.13.2.2. By Infection 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Product 16.14.2.2. By Infection 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Product 16.15.2.2. By Infection 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Product 16.16.2.2. By Infection 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Product 16.17.2.2. By Infection 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Product 16.18.2.2. By Infection 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Product 16.19.2.2. By Infection 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Product 16.20.2.2. By Infection 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Product 16.21.2.2. By Infection 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product 17.3.3. By Infection 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Thermo Fisher Scientific 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Abbott Laboratories 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Danaher Corporation 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Becton, Dickinson and Company 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Hoffmann-La Roche Ltd. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. bioMérieux Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Altona Diagnostics 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Mylab Discovery Solutions Pvt Ltd. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Siemens Healthineers AG 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Sysmex Corporation 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Respiratory Pathogen Testing Kits Market
